Amgen Inc. $AMGN Stock: ProShare Advisors LLC Boosts Stake

ProShare Advisors LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 2.3% during the third quarter, Holdings Channel.com reports. The firm owned 713,097 shares of the medical research company’s stock after buying an additional 16,067 shares during the period. Amgen makes up 0.4% of ProShare Advisors LLC’s holdings, making the stock its 28th biggest holding. ProShare Advisors LLC’s holdings in Amgen were worth $300,578,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Rational Advisors Inc. raised its stake in shares of Amgen by 13.7% in the second quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock valued at $72,000 after acquiring an additional 24 shares in the last quarter. Beacon Financial Advisory LLC lifted its position in shares of Amgen by 2.0% during the 2nd quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock valued at $461,000 after acquiring an additional 25 shares during the last quarter. James T. Borello RIA boosted its holdings in Amgen by 13.6% in the third quarter. James T. Borello RIA now owns 209 shares of the medical research company’s stock worth $88,000 after purchasing an additional 25 shares in the last quarter. Sweeney & Michel LLC boosted its holdings in Amgen by 0.5% during the third quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company’s stock valued at $2,162,000 after purchasing an additional 25 shares in the last quarter. Finally, Legacy Financial Advisors Inc. increased its position in shares of Amgen by 0.8% in the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock valued at $1,234,000 after buying an additional 26 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 1.1%

AMGN stock opened at $466.01 on Friday. Amgen Inc. has a one year low of $288.00 and a one year high of $475.65. The company’s 50 day moving average price is $419.96 and its two-hundred day moving average price is $374.79. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The company has a market capitalization of $251.94 billion, a PE ratio of 28.96, a price-to-earnings-growth ratio of 3.41 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The firm had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same period in the prior year, the business posted $6.02 EPS. Amgen’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, analysts predict that Amgen Inc. will post 22.96 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a yield of 2.2%. Amgen’s dividend payout ratio is currently 62.65%.

Insider Activity at Amgen

In other news, SVP Nancy Grygiel sold 2,970 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 in the last three months. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Mizuho increased their price objective on Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a report on Tuesday, August 18th. Guggenheim lowered their price target on shares of Amgen from $388.00 to $378.00 and set a “neutral” rating on the stock in a research report on Tuesday, October 13th. Bank of America raised their price objective on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. Wells Fargo & Company decreased their price objective on Amgen from $435.00 to $430.00 and set an “equal weight” rating on the stock in a research note on Monday, October 12th. Finally, HSBC downgraded Amgen from a “buy” rating to a “hold” rating and decreased their price target for the stock from $445.00 to $425.00 in a research note on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $389.71.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Dividend support: Amgen’s dividend announcement helped reinforce the stock’s income appeal and contributed to its move to a new 1-year high. Amgen Sets New 1-Year High Following Dividend Announcement
• Positive Sentiment: Analyst endorsement: RBC Capital reaffirmed its Buy rating, providing continued Wall Street support ahead of the earnings release. RBC Capital Reaffirms Buy Rating
• Positive Sentiment: Pipeline and rare-disease progress: New Phase 3 dazodalibep data in Sjögren’s disease, UPLIZNA updates and a rare-disease diagnostic collaboration support Amgen’s longer-term growth narrative beyond its established products. Rare Disease Updates
• Neutral Sentiment: Key near-term catalyst: Amgen will report third-quarter 2026 results after the market close on November 3. The current consensus EPS estimate cited in previews is $5.79, making earnings, guidance and management commentary important tests for the recent rally. Amgen Q3 2026 Preview
• Negative Sentiment: Profitability concerns: Management has warned of rising expenses, while MariTide development is consuming substantial cash. Investors are watching whether growth from Repatha and TEZSPIRE can offset higher costs and protect margins. Amgen Faces Rising Expenses Ahead of Q3 Results
• Negative Sentiment: Valuation and execution risk: A skeptical earnings preview highlights concerns about the CFO transition, spending growth and whether Amgen can meet expectations after a substantial year-to-date advance. Amgen Earnings Preview

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.